- 1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes
-
Hannah Seok, Ji Hye Huh, Hyun Min Kim, Byung-Wan Lee, Eun Seok Kang, Hyun Chul Lee, Bong Soo Cha
-
Diabetes Metab J. 2015;39(2):164-170. Published online March 9, 2015
-
DOI: https://doi.org/10.4093/dmj.2015.39.2.164
-
-
4,795
View
-
50
Download
-
22
Web of Science
-
21
Crossref
-
 Abstract
 PDF PubReader
- Background
Type 1 diabetes is associated with more severe glycemic variability and more frequent hypoglycemia than type 2 diabetes. Glycemic variability is associated with poor glycemic control and diabetic complications. In this study, we demonstrate the clinical usefulness of serum 1,5-anhydroglucitol (1,5-AG) for assessing changes in glycemic excursion in type 1 diabetes. MethodsSeventeen patients with type 1 diabetes were enrolled in this study. A continuous glucose monitoring system (CGMS) was applied twice at a 2-week interval to evaluate changes in glycemic variability. The changes in serum glycemic assays, including 1,5-AG, glycated albumin and hemoglobin A1c (HbA1c), were also evaluated. ResultsMost subjects showed severe glycemic excursions, including hypoglycemia and hyperglycemia. The change in 1,5-AG level was significantly correlated with changes in the glycemic excursion indices of the standard deviation (SD), mean amplitude of glucose excursion (MAGE), lability index, mean postmeal maximum glucose, and area under the curve for glucose above 180 mg/dL (r=-0.576, -0.613, -0.600, -0.630, and -0.500, respectively; all P<0.05). Changes in glycated albumin were correlated with changes in SD and MAGE (r=0.495 and 0.517, respectively; all P<0.05). However, changes in HbA1c were not correlated with any changes in the CGMS variables. Conclusion1,5-AG may be a useful marker for the assessment of short-term changes in glycemic variability. Furthermore, 1,5-AG may have clinical implications for the evaluation and treatment of glycemic excursions in type 1 diabetes.
-
Citations
Citations to this article as recorded by  - The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications
Huijuan Xu, Junhua Pan, Qiu Chen
Frontiers in Endocrinology.2024;[Epub] CrossRef - Glycation and Glucose Variability in Subjects with Type 1 Diabetes
V. V. Klimontov, D. M. Bulumbaeva, J. F. Semenova
Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry.2024; 18(1): 59. CrossRef - Glycemic dispersion: a new index for screening high glycemic variability
Rui Shi, Lei Feng, Yan-Mei Liu, Wen-Bo Xu, Bei-Bei Luo, Ling-Tong Tang, Qian-Ye Bi, Hui-Ying Cao
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef - Digital Behavior Change Interventions to Reduce Sedentary Behavior and Promote Physical Activity in Adults with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Xiaoyan Zhang, Xue Qiao, Ke Peng, Shan Gao, Yufang Hao
International Journal of Behavioral Medicine.2023;[Epub] CrossRef - DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia
Joseph P. Dewulf, Nathalie Chevalier, Sandrine Marie, Maria Veiga-da-Cunha
Molecular Genetics and Metabolism.2023; 140(3): 107712. CrossRef - The correlation between serum 1, 5-anhydroglucitol and β-cell function in Chinese adults with different glucose metabolism statuses
Yuexing Yuan, Yuanyuan Tan, Yao Wang, Shanhu Qiu, Jiao Yang, Cheng Chen
International Journal of Diabetes in Developing Countries.2023;[Epub] CrossRef - HbA1c combined with glycated albumin or 1,5‐anhydroglucitol improves the efficiency of diabetes screening in a Chinese population
Junyi Qian, Cheng Chen, Xiaohang Wang, Yuanyuan Tan, Jiao Yang, Yuexing Yuan, Juan Chen, Haijian Guo, Bei Wang, Zilin Sun, Yao Wang
Diabetic Medicine.2022;[Epub] CrossRef - Assessment of glycemia in chronic kidney disease
Mohamed Hassanein, Tariq Shafi
BMC Medicine.2022;[Epub] CrossRef - Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes
Emma S. Scott, Andrzej S. Januszewski, Luke M. Carroll, Gregory R. Fulcher, Mugdha V. Joglekar, Anandwardhan A. Hardikar, Timothy W. Jones, Elizabeth A. Davis, Alicia J. Jenkins
Scientific Reports.2021;[Epub] CrossRef - Red rice koji extract alleviates hyperglycemia by increasing glucose uptake and glucose transporter type 4 levels in skeletal muscle in two diabetic mouse models
Takakazu Yagi, Koji Ataka, Kai-Chun Cheng, Hajime Suzuki, Keizaburo Ogata, Yumiko Yoshizaki, Kazunori Takamine, Ikuo Kato, Shouichi Miyawaki, Akio Inui, Akihiro Asakawa
Food & Nutrition Research.2020;[Epub] CrossRef - How tightly controlled do fluctuations in blood glucose levels need to be to reduce the risk of developing complications in people with Type 1 diabetes?
R. Livingstone, J. G. Boyle, J. R. Petrie
Diabetic Medicine.2020; 37(4): 513. CrossRef - Resolution on the results of the first working meeting of the scientific advisory board «Actual problems of glycemic variability as a new criterion of glycemic control and safety of diabetes therapy»
Mikhail B. Antsiferov, Gagik R. Galstyan, Alexey V. Zilov, Alexander Y. Mayorov, Tatyana N. Markova, Nikolay A. Demidov, Olga M. Koteshkova, Dmitry N. Laptev, Alisa V. Vitebskaya
Diabetes mellitus.2019; 22(3): 281. CrossRef - Hyperglycemia and Carotenoid Intake Are Associated with Serum Carotenoids in Youth with Type 1 Diabetes
Namrata Sanjeevi, Leah M. Lipsky, Tonja R. Nansel
Journal of the Academy of Nutrition and Dietetics.2019; 119(8): 1340. CrossRef - Correlation of Serum 1,5-AG with Uric Acid in Type 2 Diabetes Mellitus with Different Renal Functions
Kai Zhang, Bizhen Xue, Yuexing Yuan, Yao Wang
International Journal of Endocrinology.2019; 2019: 1. CrossRef - Glycaemic control and glycaemic variability in older people with diabetes
Hermes J Florez
The Lancet Diabetes & Endocrinology.2018; 6(6): 433. CrossRef - Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes
Christine L. Chan, Laura Pyle, Megan M. Kelsey, Lindsey Newnes, Amy Baumgartner, Philip S. Zeitler, Kristen J. Nadeau
Pediatric Diabetes.2017; 18(7): 629. CrossRef - 1,5-anidroglucitolo: un marcatore non tradizionale di iperglicemia
Gabriella Lavalle, Roberto Testa, Maria Elisabetta Onori, Raffaella Vero, Anna Vero
La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine.2017; 13(3-4): 139. CrossRef - Glycemic control and variability in association with body mass index and body composition over 18months in youth with type 1 diabetes
Leah M. Lipsky, Benjamin Gee, Aiyi Liu, Tonja R. Nansel
Diabetes Research and Clinical Practice.2016; 120: 97. CrossRef - How Can We Easily Measure Glycemic Variability in Diabetes Mellitus?
Suk Chon
Diabetes & Metabolism Journal.2015; 39(2): 114. CrossRef - Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol
Ji-Eun Lee
Annals of Pediatric Endocrinology & Metabolism.2015; 20(2): 74. CrossRef - Glycemic Variability: How Do We Measure It and Why Is It Important?
Sunghwan Suh, Jae Hyeon Kim
Diabetes & Metabolism Journal.2015; 39(4): 273. CrossRef
- The Glycated Albumin to Glycated Hemoglobin Ratio Might Not Be Associated with Carotid Atherosclerosis in Patients with Type 1 Diabetes
-
Wonjin Kim, Kwang Joon Kim, Byung-Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
-
Diabetes Metab J. 2014;38(6):456-463. Published online December 15, 2014
-
DOI: https://doi.org/10.4093/dmj.2014.38.6.456
-
-
4,600
View
-
35
Download
-
10
Web of Science
-
11
Crossref
-
Abstract
PDFPubReader
- Background
The ratio of glycated albumin to glycated hemoglobin (GA/A1c) is known to be elevated in subjects with type 2 diabetes mellitus (T2DM) who had decreased insulin secretion. Additionally, the carotid intima media thickness (IMT) is greater in T2DM patients with higher GA/A1c ratios. We investigated whether increased GA/A1c ratio and IMT are also associated in type 1 diabetes mellitus (T1DM), which is characterized by lack of insulin secretory capacity. MethodsIn this cross-sectional study, we recruited 81 T1DM patients (33 men, 48 women; mean age 44.1±13.0 years) who underwent carotid IMT, GA, and HbA1c measurements. ResultsThe mean GA/A1c ratio was 2.90. Based on these results, we classified the subjects into two groups: group I (GA/A1c ratio <2.90, n=36) and group II (GA/A1c ratio ≥2.90, n=45). Compared with group I, the body mass indexes (BMIs), waist circumferences, and IMTs were lower in group II. GA/A1c ratio was negatively correlated with BMI, urine albumin to creatinine ratio (P<0.001 for both), and both the mean and maximal IMT (P=0.001, both). However, after adjusting the confounding factors, we observed that IMT was no longer associated with GA/A1c ratio. ConclusionIn contrast to T2DM, IMT was not significantly related to GA/A1c ratio in the subjects with T1DM. This suggests that the correlations between GA/A1c ratio and the parameters known to be associated with atherosclerosis in T2DM could be manifested differently in T1DM. Further studies are needed to investigate these relationships in T1DM.
-
Citations
Citations to this article as recorded by - High glycated albumin is associated with early neurological deterioration in patients with acute ischemic stroke
Ki-Woong Nam, Jung Hoon Han, Chi Kyung Kim, Hyung-Min Kwon, Yong-Seok Lee, Kyungmi Oh, Keon-Joo Lee, Byeongsu Park
BMC Neurology.2024;[Epub] CrossRef - Glycated Albumin and Glycated Albumin/HbA1c Predict the Progression of Coronavirus Disease 2019 from Mild to Severe Disease in Korean Patients with Type 2 Diabetes
Jeongseon Yoo, Youngah Choi, Shin Ae Park, Ji Yeon Seo, Chul Woo Ahn, Jaehyun Han
Journal of Clinical Medicine.2022; 11(9): 2327. CrossRef - Variability in glycated albumin levels predicts the progression of diabetic nephropathy
Su Bin Park, Sang Soo Kim, In Joo Kim, Yoon Jeong Nam, Kang Hee Ahn, Jong Ho Kim, Yun Kyung Jeon, Bo Hyun Kim, Sang Heon Song, Ihm Soo Kwak, Eun Kyung Lee, Yong Ki Kim
Journal of Diabetes and its Complications.2017; 31(6): 1041. CrossRef - Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease
Gyuri Kim, Kwang Joon Kim, Yumie Rhee, Sung-Kil Lim, Salvatore Petta
PLOS ONE.2017; 12(7): e0182202. CrossRef - Determinants of Preclinical Atherosclerosis Are Different in Type 1 and Type 2 Diabetic Women
P. PIŤHOVÁ, K. ŠTECHOVÁ, J. PIŤHA, V. LÁNSKÁ, M. KVAPIL
Physiological Research.2016; : 219. CrossRef - Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes
Gyuri Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Byung-Wan Lee
Yonsei Medical Journal.2016; 57(6): 1395. CrossRef - Visceral adiposity is associated with altered myocardial glucose uptake measured by 18FDG-PET in 346 subjects with normal glucose tolerance, prediabetes, and type 2 diabetes
Gyuri Kim, Kwanhyeong Jo, Kwang Joon Kim, Yong-ho Lee, Eugene Han, Hye-jin Yoon, Hye Jin Wang, Eun Seok Kang, Mijin Yun
Cardiovascular Diabetology.2015;[Epub] CrossRef - Glycated albumin and the risk of micro- and macrovascular complications in subjects with Type 1 Diabetes
Hye-jin Yoon, Yong-ho Lee, So Ra Kim, Tyler Hyungtaek Rim, Eun Young Lee, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Byung-Wan Lee
Cardiovascular Diabetology.2015;[Epub] CrossRef - Comparison of Candidate Pairs of Hydrolytic Enzymes for Spectrophotometric-dual-enzyme-simultaneous-assay
Hongbo Liu, Mei Yuan, Xiaolan Yang, Xiaolei Hu, Juan Liao, Jizheng Dang, Yanling Xie, Jun Pu, Yuanli Li, Chang-Guo Zhan, Fei Liao
Analytical Sciences.2015; 31(5): 421. CrossRef - Glycated Albumin Levels in Patients with Type 2 Diabetes Increase Relative to HbA1cwith Time
Hye-jin Yoon, Yong-ho Lee, Kwang Joon Kim, So Ra Kim, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Byung-Wan Lee
BioMed Research International.2015; 2015: 1. CrossRef - Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama Study
Naoko Mukai, Toshiharu Ninomiya, Jun Hata, Yoichiro Hirakawa, Fumie Ikeda, Masayo Fukuhara, Taeko Hotta, Masafumi Koga, Udai Nakamura, Dongchon Kang, Takanari Kitazono, Yutaka Kiyohara
Cardiovascular Diabetology.2015;[Epub] CrossRef
- The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
-
Eun Yeong Choe, Yongin Cho, Younjeong Choi, Yujung Yun, Hye Jin Wang, Obin Kwon, Byung-Wan Lee, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang
-
Diabetes Metab J. 2014;38(3):211-219. Published online June 17, 2014
-
DOI: https://doi.org/10.4093/dmj.2014.38.3.211
-
-
5,284
View
-
76
Download
-
27
Web of Science
-
25
Crossref
-
Abstract
PDF
 Supplementary MaterialPubReader
- Background
We evaluated the effects of two dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and vildagliptin, on metabolic parameters in patients with type 2 diabetes mellitus. MethodsA total of 170 type 2 diabetes patients treated with sitagliptin or vildagliptin for more than 24 weeks were selected. The patients were separated into two groups, sitagliptin (100 mg once daily, n=93) and vildagliptin (50 mg twice daily, n=77). We compared the effect of each DPP-4 inhibitor on metabolic parameters, including the fasting plasma glucose (FPG), postprandial glucose (PPG), glycated hemoglobin (HbA1c), and glycated albumin (GA) levels, and lipid parameters at baseline and after 24 weeks of treatment. ResultsThe HbA1c, FPG, and GA levels were similar between the two groups at baseline, but the sitagliptin group displayed a higher PPG level (P=0.03). After 24 weeks of treatment, all of the glucose-related parameters were significantly decreased in both groups (P=0.001). The levels of total cholesterol and triglycerides were only reduced in the vildagliptin group (P=0.001), although the sitagliptin group received a larger quantity of statins than the vildagliptin group (P=0.002).The mean change in the glucose- and lipid-related parameters after 24 weeks of treatment were not significantly different between the two groups (P=not significant). Neither sitagliptin nor vildagliptin treatment was associated with a reduction in the high sensitive C-reactive protein level (P=0.714). ConclusionVildagliptin and sitagliptin exert a similar effect on metabolic parameters, but vildagliptin exerts a more potent beneficial effect on lipid parameters.
-
Citations
Citations to this article as recorded by
- Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients
-
Young Ki Lee, Sun Ok Song, Kwang Joon Kim, Yongin Cho, Younjeong Choi, Yujung Yun, Byung-Wan Lee, Eun-Seok Kang, Bong Soo Cha, Hyun Chul Lee
-
Diabetes Metab J. 2013;37(6):465-474. Published online December 12, 2013
-
DOI: https://doi.org/10.4093/dmj.2013.37.6.465
-
-
5,737
View
-
76
Download
-
18
Crossref
-
Abstract
PDFPubReader
- Background
This study compared the glycemic effectiveness of three metformin-based dual therapies according to baseline hemoglobin A1c (HbA1c) to evaluate the appropriateness of the guideline enforced by the National Health Insurance Corporation of Korea for initial medication of type 2 diabetes (T2D). MethodsThis prospective observational study was conducted across 24 weeks for drug-naïve Korean T2D patients with HbA1c greater than 7.5%. Subjects were first divided into three groups based on the agent combined with metformin (group 1, gliclazide-modified release or glimepiride; group 2, pioglitazone; group 3, sitagliptin). Subjects were also classified into three categories according to baseline HbA1c (category I, 7.5%≤HbA1c<9.0%; category II, 9.0%≤HbA1c<11.0%; category III, 11.0%≤HbA1c). ResultsAmong 116 subjects, 99 subjects completed the study, with 88 subjects maintaining the initial medication. While each of the metformin-based dual therapies showed a significant decrease in HbA1c (group 1, 8.9% to 6.4%; group 2, 9.0% to 6.6%; group 3, 9.3% to 6.3%; P<0.001 for each), there was no significant difference in the magnitude of HbA1c change among the groups. While the three HbA1c categories showed significantly different baseline HbA1c levels (8.2% vs. 9.9% vs. 11.9%; P<0.001), endpoint HbA1c was not different (6.4% vs. 6.6% vs. 6.0%; P=0.051). ConclusionThe three dual therapies using a combination of metformin and either sulfonylurea, pioglitazone, or sitagliptin showed similar glycemic effectiveness among drug-naïve Korean T2D patients. In addition, these regimens were similarly effective across a wide range of baseline HbA1c levels.
-
Citations
Citations to this article as recorded by - Benefits and risks of drug combination therapy for diabetes mellitus and its complications: a comprehensive review
Xueqin Xie, Changchun Wu, Yuduo Hao, Tianyu Wang, Yuhe Yang, Peiling Cai, Yang Zhang, Jian Huang, Kejun Deng, Dan Yan, Hao Lin
Frontiers in Endocrinology.2023;[Epub] CrossRef - Estimation of Serum Creatinine, Aspartate Aminotransferase, Alanine Transaminase, and Hemoglobin A1c% Levels among Diabetic Patients using Metformin/Dipeptide Peptidase-4 Inhibitor Combination and Insulin – A Cross-Sectional Study
Arshiya Shadab, Ilma Hussain, Praveen Kumar Kandakurti, Marwan Ismail, Ahmed Luay Osman Hashim, Salah Eldin Omar Hussein, Altoum Abd Elgadir
Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 959. CrossRef - Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Hae Kyung Yang, Seung-Hwan Lee, Juyoung Shin, Yoon-Hee Choi, Yu-Bae Ahn, Byung-Wan Lee, Eun Jung Rhee, Kyung Wan Min, Kun-Ho Yoon
Diabetes & Metabolism Journal.2019; 43(3): 287. CrossRef - Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24-week real-life study from Asia
Manoj Chawla, Tae Ho Kim, Roberto C. Mirasol, Pathan Faruque, Kathryn Cooke, Peggy Hours-Zesiger, Abhijit Shete
Current Medical Research and Opinion.2018; 34(9): 1605. CrossRef - Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force
Sanjay Kalra, Silver Bahendeka, Rakesh Sahay, Sujoy Ghosh, Fariduddin Md, Abbas Orabi, Kaushik Ramaiya, Sameer Al Shammari, Dina Shrestha, Khalid Shaikh, Sachitha Abhayaratna, PradeepK Shrestha, Aravinthan Mahalingam, Mazen Askheta, AlyAhmed A. Rahim, Fat
Indian Journal of Endocrinology and Metabolism.2018; 22(1): 132. CrossRef - Efficacy and safety of sitagliptin/metformin fixed‐dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double‐blind study
Sang Soo Kim, In Joo Kim, Kwang Jae Lee, Jeong Hyun Park, Young Il Kim, Young Sil Lee, Sung Chang Chung, Sang Jin Lee
Journal of Diabetes.2017; 9(4): 412. CrossRef - Short‐term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9%
Jianping Weng
Journal of Diabetes.2017; 9(10): 890. CrossRef - The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus
Gyuri Kim, Sewon Oh, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim, Moon-Kyu Lee
Expert Opinion on Pharmacotherapy.2017; 18(12): 1179. CrossRef - Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis
Elena Filipova, Katya Uzunova, Krassimir Kalinov, Toni Vekov
Diabetology & Metabolic Syndrome.2017;[Epub] CrossRef - Is insulin the preferred treatment for HbA1c >9%?
Zachary Bloomgarden
Journal of Diabetes.2017; 9(9): 814. CrossRef - Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis
Manuj Sharma, Nicholas Beckley, Irwin Nazareth, Irene Petersen
BMJ Open.2017; 7(10): e017260. CrossRef - The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients
Nasser Aghamohammadzadeh, Mitra Niafar, Elham Dalir Abdolahinia, Farzad Najafipour, Saeed Mohamadzadeh Gharebaghi, Khadijeh Adabi, Elaheh Dalir Abdolahinia, Hamidreza Ahadi
Therapeutic Advances in Endocrinology and Metabolism.2015; 6(2): 56. CrossRef - Glycated Albumin Levels in Patients with Type 2 Diabetes Increase Relative to HbA1cwith Time
Hye-jin Yoon, Yong-ho Lee, Kwang Joon Kim, So Ra Kim, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Byung-Wan Lee
BioMed Research International.2015; 2015: 1. CrossRef - Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study
Eu Jeong Ku, Kyong Yeon Jung, Yoon Ji Kim, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Soo Lim, Bo Ahrén, Giorgio Sesti
PLOS ONE.2015; 10(6): e0129477. CrossRef - Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins
Elena Pavlova Filipova, Katya Hristova Uzunova, Toni Yonkov Vekov
Diabetology & Metabolic Syndrome.2015;[Epub] CrossRef - Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition
Sen Shi, Swayam Prakash Srivastava, Megumi Kanasaki, Jianhua He, Munehiro Kitada, Takako Nagai, Kyoko Nitta, Susumu Takagi, Keizo Kanasaki, Daisuke Koya
Kidney International.2015; 88(3): 479. CrossRef - Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors: New among Antidiabetic Drugs
L. H. Opie
Cardiovascular Drugs and Therapy.2014; 28(4): 331. CrossRef - Metformin Based Dual-Combination Therapies in Drug Naïve Type 2 Diabetic Patients
Dong-Lim Kim
Diabetes & Metabolism Journal.2013; 37(6): 429. CrossRef
- The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone
-
Sun Ok Song, Kwang Joon Kim, Byung-Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
-
Diabetes Metab J. 2012;36(5):371-378. Published online October 18, 2012
-
DOI: https://doi.org/10.4093/dmj.2012.36.5.371
-
-
4,785
View
-
33
Download
-
30
Crossref
-
Abstract
PDFPubReader
- Background
There is growing concern regarding the increased incidence of bladder cancer in diabetic patients using pioglitazone. This study aimed to investigate the association between bladder cancer and the use of pioglitazone in Korean diabetics. MethodsThis retrospective, matched case-control study included a case group (n=329) of diabetic patients with bladder cancer who presented at the Severance Hospital from November 2005 to June 2011. The control group consisted of patients without bladder cancer (1:2 ratio matching for sex and age, n=658) who were listed on the Severance Hospital diabetes registry. ResultsThe percentage of subjects who had ever used pioglitazone was significantly lower in the case group than in the control group (6.4% vs. 15.0%, P<0.001). Multivariate conditional logistic analysis revealed that independent factors affecting bladder cancer were smoking (odds ratio [OR], 11.64; 95% confidence interval [CI], 6.56 to 20.66; P<0.001), coexisting cancer (OR, 6.11; 95% CI, 2.25 to 16.63; P<0.001), and hemoglobin levels (OR, 0.78; 95% CI, 0.69 to 0.88; P<0.001). The OR of the history of pioglitazone use was 2.09 and was not significantly different between the two groups (95% CI, 0.26 to 16.81; P=0.488). ConclusionA relationship between pioglitazone use and incidence of bladder cancer was not observed in Korean diabetic patients. This suggests that the risk for bladder cancer in Korean diabetic subjects treated with pioglitazone might be different from that of Caucasian populations. Large-scale, well-designed and multi-center studies are needed to further evaluate this relationship.
-
Citations
Citations to this article as recorded by - Cancer biology in diabetes update: Focusing on antidiabetic drugs
Emi Kawakita, Keizo Kanasaki
Journal of Diabetes Investigation.2024; 15(5): 525. CrossRef - Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Georgios S. Papaetis
Current Drug Safety.2022; 17(4): 294. CrossRef - A systematic review of observational studies of the association between pioglitazone use and bladder cancer
E. Ripamonti, L. Azoulay, M. Abrahamowicz, R.W. Platt, S. Suissa
Diabetic Medicine.2019; 36(1): 22. CrossRef - Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type‐2 diabetes
Elizabeth M. Garry, John B. Buse, Mugdha Gokhale, Jennifer L. Lund, Matthew E. Nielsen, Virginia Pate, Til Stürmer
Diabetes, Obesity and Metabolism.2019; 21(9): 2096. CrossRef - Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies
Juha Mehtälä, Houssem Khanfir, Dimitri Bennett, Yizhou Ye, Pasi Korhonen, Fabian Hoti
Diabetology International.2019; 10(1): 24. CrossRef - Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Melissa A. Davidson, Donald R. Mattison, Laurent Azoulay, Daniel Krewski
Critical Reviews in Toxicology.2018; 48(1): 52. CrossRef - An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitis
Mayer B. Davidson, Deyu Pan
Diabetes Research and Clinical Practice.2018; 135: 102. CrossRef - Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic literature review and meta-analysis of observational studies using real-world data
Mohammad Adil, Rashid Ali Khan, Pinaki Ghosh, Shiva Kumar Venkata, Amit Dattatraya Kandhare, Manju Sharma
Clinical Epidemiology and Global Health.2018; 6(2): 61. CrossRef - Pioglitazone and bladder cancer risk: a systematic review and meta‐analysis
Huilin Tang, Weilong Shi, Shuangshuang Fu, Tiansheng Wang, Suodi Zhai, Yiqing Song, Jiali Han
Cancer Medicine.2018; 7(4): 1070. CrossRef - Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes
Hua Qu, Yi Zheng, Yuren Wang, Rui Zhang, Xiongzhong Ruan, Gangyi Yang, Zhenqi Liu, Hongting Zheng
Scientific Reports.2017;[Epub] CrossRef - Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Elena Filipova, Katya Uzunova, Krassimir Kalinov, Toni Vekov
Diabetes Therapy.2017; 8(4): 705. CrossRef - Pioglitazone does not increase the risk of type II diabetes in patients with bladder cancer: A retrospective study
YOUHONG DONG, ANPING WANG
Oncology Letters.2016; 12(1): 89. CrossRef - Ten‐year observational follow‐up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
E. Erdmann, S. Harding, H. Lam, A. Perez
Diabetes, Obesity and Metabolism.2016; 18(3): 266. CrossRef - Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence
Mayer B. Davidson
Journal of Diabetes and its Complications.2016; 30(6): 981. CrossRef - The current role of thiazolidinediones in diabetes management
Christos V. Rizos, Anastazia Kei, Moses S. Elisaf
Archives of Toxicology.2016; 90(8): 1861. CrossRef - Development of vascular complications and bladder carcinoma in diabetics using pioglitazone: A five-year Indian review
Saarwaani Vallabhajosyula, Shashaank Vallabhajosyula, Saraschandra Vallabhajosyula, Suma Nair, Asha Kamath, Karthik N. Rao
Medical Journal Armed Forces India.2016; 72(3): 253. CrossRef - Baseline glycemic status and mortality in 241,499 Korean metropolitan subjects: A Kangbuk Samsung Health Study
Eun-Jung Rhee, Se Eun Park, Yoosoo Chang, Seungho Ryu, Won-Young Lee
Metabolism.2016; 65(2): 68. CrossRef - Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes
Eugene Han, Suk-Yong Jang, Gyuri Kim, Yong-ho Lee, Eun Yeong Choe, Chung Mo Nam, Eun Seok Kang
Medicine.2016; 95(6): e2786. CrossRef - Polemics of pioglitazone: an appraisal in 2015
Awadhesh Kumar Singh
Expert Review of Endocrinology & Metabolism.2015; 10(4): 447. CrossRef - Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis
Daniel Levin, Samira Bell, Reijo Sund, Sirpa A. Hartikainen, Jaakko Tuomilehto, Eero Pukkala, Ilmo Keskimäki, Ellena Badrick, Andrew G. Renehan, Iain E. Buchan, Samantha L. Bowker, Jasjeet K. Minhas-Sandhu, Zafar Zafari, Carlo Marra, Jeffrey A. Johnson, B
Diabetologia.2015; 58(3): 493. CrossRef - Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis
Richard M. Turner, Chun S. Kwok, Chen Chen‐Turner, Chinedu A. Maduakor, Sonal Singh, Yoon K. Loke
British Journal of Clinical Pharmacology.2014; 78(2): 258. CrossRef - A Review on Thiazolidinediones and Bladder Cancer in Human Studies
Chin-Hsiao Tseng
Journal of Environmental Science and Health, Part C.2014; 32(1): 1. CrossRef - Physiological Functions of Peroxisome Proliferator-Activated Receptor β
Jaap G. Neels, Paul A. Grimaldi
Physiological Reviews.2014; 94(3): 795. CrossRef - Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study
Sang-Man Jin, Sun Ok Song, Chang Hee Jung, Jin-Sun Chang, Sunghwan Suh, Seung Min Kang, Inkyung Jung, Cheol-Young Park, Jae Hyeon Kim, Jae Hyoung Cho, Byung-Wan Lee
Journal of Korean Medical Science.2014; 29(2): 238. CrossRef - Pioglitazone
SS Jadhav, VK Shivane, AR Lila, TR Bandgar, NS Shah
Journal of Postgraduate Medicine.2014; 60(3): 293. CrossRef - Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes
Hannah Seok, Bong Soo Cha
Diabetes & Metabolism Journal.2013; 37(5): 326. CrossRef - Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report
Hirofumi Suzuki, Masaya Sakamoto, Takeshi Hayashi, Hiroyuki Iuchi, Kennosuke Ohashi, Tsuyoshi Isaka, Noriko Sakamoto, Yosuke Kayama, Katsuyoshi Tojo, Michihiro Yoshimura, Kazunori Utsunomiya
Cardiovascular Diabetology.2013;[Epub] CrossRef - The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Hanford Yau, Kathya Rivera, Romina Lomonaco, Kenneth Cusi
Current Diabetes Reports.2013; 13(3): 329. CrossRef - Letter: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J2012;36:371-8)
Sheyu Li, Haoming Tian
Diabetes & Metabolism Journal.2013; 37(1): 81. CrossRef - Metabolic Surgery for Type 2 Diabetes in Patients with a BMI of <35 kg/m2: A Surgeon’s Perspective
Ricardo Cohen, Pedro Paulo Caravatto, Tarissa Petry
Obesity Surgery.2013; 23(6): 809. CrossRef
- Balsamic Vinegar Improves High Fat-Induced Beta Cell Dysfunction via Beta Cell ABCA1
-
Hannah Seok, Ji Young Lee, Eun Mi Park, Se Eun Park, Jae Hyuk Lee, Seungtaek Lim, Byung-Wan Lee, Eun Seok Kang, Hyun Chul Lee, Bong Soo Cha
-
Diabetes Metab J. 2012;36(4):275-279. Published online August 20, 2012
-
DOI: https://doi.org/10.4093/dmj.2012.36.4.275
-
-
5,155
View
-
51
Download
-
9
Crossref
-
Abstract
PDFPubReader
- Background
The aim of this study was to investigate the effects of balsamic vinegar on β-cell dysfunction. MethodsIn this study, 28-week-old Otsuka Long-Evans Tokushima Fatty (OLETF) rats were fed a normal chow diet or a high-fat diet (HFD) and were provided with tap water or dilute balsamic vinegar for 4 weeks. Oral glucose tolerance tests and histopathological analyses were performed thereafter. ResultsIn rats fed both the both chow diet and the HFD, the rats given balsamic vinegar showed increased insulin staining in islets compared with tap water administered rats. Balsamic vinegar administration also increased β-cell ATP-binding cassette transporter subfamily A member 1 (ABCA1) expression in islets and decreased cholesterol levels. ConclusionThese findings provide the first evidence for an anti-diabetic effect of balsamic vinegar through improvement of β-cell function via increasing β-cell ABCA1 expression.
-
Citations
Citations to this article as recorded by - The herbal extract ALS-L1023 from Melissa officinalis reduces weight gain, elevated glucose levels and β-cell loss in Otsuka Long-Evans Tokushima fatty rats
Yujin Shin, Dongju Lee, Jiwon Ahn, Mijeong Lee, Soon Shik Shin, Michung Yoon
Journal of Ethnopharmacology.2021; 264: 113360. CrossRef - The Effect of Balsamic Vinegar Dressing on Protein and Carbohydrate Digestibility is Dependent on the Food Matrix
Eleonora Urbinati, Mattia Di Nunzio, Gianfranco Picone, Elena Chiarello, Alessandra Bordoni, Francesco Capozzi
Foods.2021; 10(2): 411. CrossRef - Safety and side effects of apple vinegar intake and its effect on metabolic parameters and body weight: a systematic review
Tine Louise Launholt, Christina Blanner Kristiansen, Peter Hjorth
European Journal of Nutrition.2020; 59(6): 2273. CrossRef - Nypa fruticans Wurmb. Vinegar’s Aqueous Extract Stimulates Insulin Secretion and Exerts Hepatoprotective Effect on STZ-Induced Diabetic Rats
Nor Yusoff, Vuanghao Lim, Bassel Al-Hindi, Khairul Abdul Razak, Tri Widyawati, Dwi Anggraini, Mariam Ahmad, Mohd Asmawi
Nutrients.2017; 9(9): 925. CrossRef - Cholesterol in Pancreatic β-Cell Death and Dysfunction
Rajib Paul, Amarendranath Choudhury, Sabanum Choudhury, Muhammed K. Mazumder, Anupom Borah
Pancreas.2016; 45(3): 317. CrossRef - Chemical Characteristics and Immuno-Stimulatory Activity of Polysaccharides from Fermented Vinegars Manufactured with Different Raw Materials
Dong-Su Kim, Byung Serk Hurh, Kwang-Soon Shin
Journal of the Korean Society of Food Science and Nutrition.2015; 44(2): 191. CrossRef - Effect and mechanisms of action of vinegar on glucose metabolism, lipid profile, and body weight
Eleni I Petsiou, Panayota I Mitrou, Sotirios A Raptis, George D Dimitriadis
Nutrition Reviews.2014; 72(10): 651. CrossRef - Chemical Property and Macrophage Stimulating Activity of Polysaccharides isolated from Brown Rice and Persimmon Vinegars
Dong-Su Kim, Kwang-Soon Shin
The Korean Journal of Food And Nutrition.2014; 27(6): 1033. CrossRef - Vinegar ingestion at mealtime reduced fasting blood glucose concentrations in healthy adults at risk for type 2 diabetes
Carol S. Johnston, Samantha Quagliano, Serena White
Journal of Functional Foods.2013; 5(4): 2007. CrossRef
- Post-Renal Transplant Diabetes Mellitus in Korean Subjects: Superimposition of Transplant-Related Immunosuppressant Factors on Genetic and Type 2 Diabetic Risk Factors
-
Hyun Chul Lee
-
Diabetes Metab J. 2012;36(3):199-206. Published online June 14, 2012
-
DOI: https://doi.org/10.4093/dmj.2012.36.3.199
-
-
4,032
View
-
32
Download
-
9
Crossref
-
Abstract
PDFPubReader
Postrenal transplantation diabetes mellitus (PTDM), or new-onset diabetes after organ transplantation, is an important chronic transplant-associated complication. Similar to type 2 diabetes, decreased insulin secretion and increased insulin resistance are important to the pathophysiologic mechanism behind the development of PTDM. However, β-cell dysfunction rather than insulin resistance seems to be a greater contributing factor in the development of PTDM. Increased age, family history of diabetes, ethnicity, genetic variation, obesity, and hepatitis C are partially accountable for an increased underlying risk of PTDM in renal allograft recipients. In addition, the use of and kinds of immunosuppressive agents are key transplant-associated risk factors. Recently, a number of genetic variants or polymorphisms susceptible to immunosuppressants have been reported to be associated with calcineurin inhibition-induced β-cell dysfunction. The identification of high risk factors of PTDM would help prevent PTDM and improve long-term patient outcomes by allowing for personalized immunosuppressant regimens and by managing cardiovascular risk factors. -
Citations
Citations to this article as recorded by - Risk Factors Related to New-Onset Diabetes after Renal Transplantation in Patients of a High Complexity University Hospital in Colombia, 20 Years of Experience
Guillermo E. Guzmán, Angela M. Victoria, Isabella Ramos, Alejandro Maldonado, Eliana Manzi, Juan F. Contreras-Valero, Liliana Mesa, Johanna Schweineberg, Juan G. Posada, Jorge I. Villegas, Luis A. Caicedo, Carlos E. Durán
International Journal of Endocrinology.2020; 2020: 1. CrossRef - Synthesis of Fructose Biosensors and Progressing Their Efficiency Using Californium Colloidal Nanoparticles for Detecting Fructose and Triglycerides
Alireza Heidari
Advanced Science, Engineering and Medicine.2020; 12(8): 1002. CrossRef - Comparison of Glucose Tolerance between Kidney Transplant Recipients and Healthy Controls
Hisao Shimada, Junji Uchida, Shunji Nishide, Kazuya Kabei, Akihiro Kosoku, Keiko Maeda, Tomoaki Iwai, Toshihide Naganuma, Yoshiaki Takemoto, Tatsuya Nakatani
Journal of Clinical Medicine.2019; 8(7): 920. CrossRef - Diabètes post-transplantation rénale
Danièle Dubois-Laforgue
Néphrologie & Thérapeutique.2017; 13: S137. CrossRef - Risk assessment and management of post-transplant diabetes mellitus
Eugene Han, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
Metabolism.2016; 65(10): 1559. CrossRef - Renal posttransplantation diabetes mellitus: An overview
Ana Laura Pimentel, Andrea Carla Bauer, Joíza Lins Camargo
Clinica Chimica Acta.2015; 450: 327. CrossRef - HMG CoA Reductase Inhibitor Treatment Induces Dysglycemia in Renal Allograft Recipients
Eun Yeong Choe, Hye Jin Wang, Obin Kwon, Yongin Cho, Kyu Ha Huh, Myoung Soo Kim, Yu Seun Kim, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang
Transplantation.2014; 97(4): 419. CrossRef - Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels
Yongin Cho, Min Jung Lee, Eun Yeong Choe, Chang Hee Jung, Dong Jin Joo, Myoung Soo Kim, Bong Soo Cha, Joong-Yeol Park, Eun Seok Kang
Liver Transplantation.2014; 20(5): 557. CrossRef - Post-Transplant Diabetes Mellitus: Is It Associated With Poor Allograft Outcomes in Renal Transplants?
J.Y. Choi, O.J. Kwon
Transplantation Proceedings.2013; 45(8): 2892. CrossRef
- Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus
-
Eun Yeong Choe, Yong-ho Lee, Byung-Wan Lee, Eun-Seok Kang, Bong Soo Cha, Hyun Chul Lee
-
Diabetes Metab J. 2012;36(3):230-236. Published online June 14, 2012
-
DOI: https://doi.org/10.4093/dmj.2012.36.3.230
-
-
3,522
View
-
33
Download
-
6
Crossref
-
Abstract
PDFPubReader
- Background
The present study investigates the efficacy in glycemic control by adding once-a-day glulisine to glargine as a basal plus regimen and factors influencing glycemic control with the basal plus regimen in Korean subjects with type 2 diabetes. MethodsIn the present retrospective study, subjects previously treated with the basal plus regimens for at least 6 months were reviewed. Changes in glycemic profiles and clinical parameters were evaluated. ResultsA total of 87 subjects were ultimately enrolled in this study. At baseline, mean glycated hemoglobin (A1c) and glycated albumin were 8.5% (8.0% to 9.6%) and 25.2±7.6%, respectively. After treatment with the basal plus regimen, patients had significant reductions of A1c at 6 months (0.8±0.1%, P<0.001) and their postprandial glucose levels were decreased by 48.7±10.3 mg/dL (P<0.001). Multiple logistic regression showed old age (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.02 to 1.55), high initial A1c (OR, 22.21; 95% CI, 2.44 to 201.78), and lower amounts of glargine (OR, 0.85; 95% CI, 0.76 to 0.99), and glimepiride (OR, 0.23; 95% CI, 0.06 to 0.93) at baseline were independently associated with good responders whose A1c reduction was more than 0.5%. ConclusionThe authors suggest a basal plus regimen may be effective in reducing glucose levels of subjects with old age, high initial A1c, and patients on low doses of glimepiride and glargine. Despite the use of high doses of hypoglycemic agents, elderly patients with poorly-controlled diabetes are preferred for early initiation of the basal plus regimen.
-
Citations
Citations to this article as recorded by - Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen
Jochen Seufert, Anja Borck, Peter Bramlage
BMJ Open Diabetes Research & Care.2019; 7(1): e000679. CrossRef - Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment – A prospective observational study in 2202 patients
Thorsten Siegmund, Martin Pfohl, Thomas Forst, Stefan Pscherer, Peter Bramlage, Johannes Foersch, Anja Borck, Jochen Seufert
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2017; 11(1): 51. CrossRef - Characteristics Predictive for a Successful Switch from Insulin Analogue Therapy to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes
Gyuri Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Byung-Wan Lee
Yonsei Medical Journal.2016; 57(6): 1395. CrossRef - Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes
Sun Ok Song, You-Cheol Hwang, Kyu-Jeung Ahn, Bong Soo Cha, Young Duk Song, Dae Wook Lee, Byung-Wan Lee
Diabetes Therapy.2015; 6(4): 547. CrossRef - The optimal morning:evening ratio in total dose of twice‐daily biphasic insulin analogue in poorly controlled Type 2 diabetes: a 24‐week multi‐centre prospective, randomized controlled, open‐labelled clinical study
C. H. Jung, J.‐Y. Park, J. H. Cho, K.‐H. Yoon, H. K. Yang, Y.‐H. Lee, B. S. Cha, B.‐W. Lee
Diabetic Medicine.2014; 31(1): 68. CrossRef -
The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub‐analysis from the A
1
chieve
®
study
Y.‐C. Hwang, J. G. Kang, K. J. Ahn, B. S. Cha, S.‐H. Ihm, S. Lee, M. Kim, B.‐W. Lee
International Journal of Clinical Practice.2014; 68(11): 1338. CrossRef
- Associations between Fatness, Fitness, IGF and IMT among Obese Korean Male Adolescents
-
Eun Sung Kim, Ji-Hye Park, Mi Kyung Lee, Dong Hoon Lee, Eun Seok Kang, Hyun Chul Lee, Yoonsuk Jekal, Justin Y. Jeon
-
Diabetes Metab J. 2011;35(6):610-618. Published online December 26, 2011
-
DOI: https://doi.org/10.4093/dmj.2011.35.6.610
-
-
40,297
View
-
46
Download
-
15
Crossref
-
Abstract
PDFPubReader
- Background
The purpose of this study was to investigate the association between obesity, fitness levels and cardiovascular (CVD) risk factors, and to identify the correlation between of insulin-like growth factor (IGF)-1, IGF binding protein-3 (IGFBP-3), and carotid intima media thickness (IMT) in Korean adolescents. MethodsA total of 225 high school males with a mean age of 16.96±0.23 years participated in this study, and their fatness and fitness levels, fasting glucose, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), blood lipids, IGF-1, IGFBP-3, and IMT were measured. ResultsThe results showed that total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), fasting insulin, HOMA-IR, IGF-1, and IGFBP-3 levels were significantly higher in the most obese group than in the other two groups (tertiles). Muscular and cardiopulmonary fitness were negatively associated with weight, body mass index (BMI), fat mass, body fat, waist circumference (WC), fasting insulin, HOMA-IR, and IMT. IGF-1 and IGFBP-3 levels were correlated with WC, hip circumference (HC), fasting glucose, TG, HDL-C, fasting insulin, and HOMA-IR. IMT levels were significantly associated with weight, BMI, muscle mass, fat mass, percent body fat, WC, HC, systolic blood pressure, diastolic blood pressure and high-sensitivity C-reactive protein. ConclusionThere was a significant association between increased obesity and decreased fitness and HOMA-IR, IGF, and IMT among adolescents.
-
Citations
Citations to this article as recorded by - Relationship between insulin-like growth factor-1, insulin resistance and metabolic profile with pre-obesity and obesity in children
Marina Jaksic, Milica Martinovic, Najdana Gligorovic-Barhanovic, Tanja Antunovic, Mirjana Nedovic-Vukovic
Journal of Pediatric Endocrinology and Metabolism.2021; 34(3): 301. CrossRef - Enerji Metabolizması, Obezite ve Hormonlar
Derya Selda SINAR, Nasuh Evrim ACAR, İrfan YILDIRIM
Türkiye Spor Bilimleri Dergisi.2020; 4(1): 30. CrossRef - Carotid Intima‐Media Thickness but Not Carotid Artery Plaque in Healthy Individuals Is Linked to Lean Body Mass
Matthew Arnold, Andrew Linden, Robert Clarke, Yu Guo, Huaidong Du, Zheng Bian, Eric Wan, Meng Yang, Liang Wang, Yuexin Chen, Jianwei Chen, Huajun Long, Qijun Gu, Rory Collins, Liming Li, Zhengming Chen, Sarah Parish, Junshi Chen, Jun Lv, Richard Peto, Rob
Journal of the American Heart Association.2019;[Epub] CrossRef - Oxidative Stress and Inflammation, Key Targets of Atherosclerotic Plaque Progression and Vulnerability: Potential Impact of Physical Activity
Pauline Mury, Erica N. Chirico, Mathilde Mura, Antoine Millon, Emmanuelle Canet-Soulas, Vincent Pialoux
Sports Medicine.2018; 48(12): 2725. CrossRef - Protein Intake in Infancy and Carotid Intima Media Thickness at 5 Years - A Secondary Analysis from a Randomized Trial
Dariusz Gruszfeld, Martina Weber, Monika Nowakowska-Rysz, Roman Janas, Rainer Kozlik-Feldmann, Annick Xhonneux, Clotilde Carlier, Enrica Riva, Elvira Verduci, Ricardo Closa-Monasterolo, Joaquin Escribano, Anna Dobrzanska, Berthold Koletzko
Annals of Nutrition and Metabolism.2015; 66(1): 51. CrossRef - High Prevalence of Cardiometabolic Risk Factors in Hispanic Adolescents: Correlations with Adipocytokines and Markers of Inflammation
Cynthia M. Pérez, Ana P. Ortiz, Enrique Fuentes-Mattei, Guermarie Velázquez-Torres, Damarys Santiago, Katya Giovannetti, Raúl Bernabe, Mong-Hong Lee, Sai-Ching J. Yeung
Journal of Immigrant and Minority Health.2014; 16(5): 865. CrossRef - Cross-sectional and longitudinal relation of IGF1 and IGF-binding protein 3 with lipid metabolism
Marie-Luise Eggert, Henri Wallaschofski, Anne Grotevendt, Matthias Nauck, Henry Völzke, Stefanie Samietz, Nele Friedrich
European Journal of Endocrinology.2014; 171(1): 9. CrossRef - Association between insulin‐like growth factor‐1, measures of overnutrition and undernutrition and insulin resistance in black adolescents living in the north‐west province, South Africa
Ramoteme L. Mamabolo, Cristiana Berti, Makama A. Monyeki, H. Salome Kruger
American Journal of Human Biology.2014; 26(2): 189. CrossRef - Prevalence and trend of dyslipidaemia from 1996 to 2006 among normal and overweight adolescents in Taiwan
Philip Kuo, Jhu-Ting Syu, Isabel Lin Tzou, Pi-Yun Chen, Hsiu-Yueh Su, Nain-Feng Chu
BMJ Open.2014; 4(2): e003800. CrossRef - Relationship of serum insulin-like growth factor I (IGF-I) with nutritional status in pediatric patients with malignant diseases—a single Romanian center experience
Mihaela Ioana Chinceşan, Oana Mărginean, Ana-Maria Pitea, Minodora Dobreanu
European Journal of Pediatrics.2013; 172(10): 1401. CrossRef - Gene x environment interactions impact endometrial function and the menstrual cycle: PROGINS, life history, anthropometry, and physical activity
Elizabeth J. Rowe, Toby K. Eisenstein, Joseph Meissler, L. Christie Rockwell
American Journal of Human Biology.2013; 25(5): 681. CrossRef - Insulin-like growth factor-I (IGF-I) and clinical nutrition
Callum Livingstone
Clinical Science.2013; 125(6): 265. CrossRef - Higher Body Mass Index Leads to Longer Operative Time in Total Knee Arthroplasty
Barthelemy Liabaud, David A. Patrick, Jeffrey A. Geller
The Journal of Arthroplasty.2013; 28(4): 563. CrossRef - The Relationship Between Fitness, BMI and Risk Factors of Metabolic Syndrome Among University Students in Korea
Dong-il Kim, Ji Young Kim, Mi Kyoung Lee, Hae-Dong Lee, Ji-Won Lee, Justin Y. Jeon
The Korean Journal of Obesity.2012; 21(2): 99. CrossRef - The Insulin-Like Growth Factor System and Nutritional Assessment
Callum Livingstone
Scientifica.2012; 2012: 1. CrossRef
- Dietary Oleate Has Beneficial Effects on Every Step of Non-Alcoholic Fatty Liver Disease Progression in a Methionine- and Choline-Deficient Diet-Fed Animal Model
-
Ji Young Lee, Jae Hoon Moon, Jong Suk Park, Byung-Wan Lee, Eun Seok Kang, Chul Woo Ahn, Hyun Chul Lee, Bong Soo Cha
-
Diabetes Metab J. 2011;35(5):489-496. Published online October 31, 2011
-
DOI: https://doi.org/10.4093/dmj.2011.35.5.489
-
-
30,895
View
-
44
Download
-
17
Crossref
-
Abstract
PDFPubReader
- Background
Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a major cause of liver-related morbidity and mortality. The underlying mechanisms of disease progression remain poorly understood, and primary therapy of NAFLD is not yet established. We investigated the effects of dietary oleate on the development and progression of NAFLD in a methionine- and choline-deficient (MCD) diet-fed animal model. MethodsA total of 30 C57BL/6J mice were randomly divided into three groups (n=10 in each group) and fed various experimental diets for four weeks: chow, MCD diet, or OMCD (MCD diet with oleate, 0.5 mg/g/day). Liver samples were examined for steatohepatitis and fibrosis parameters and associated genes. ResultsAdditional dietary oleate dramatically reduced MCD diet-induced hepatic steatosis. Hepatic carbohydrate responsive element-binding protein was overexpressed in MCD diet-fed mice, and dietary oleate prevented this overexpression (P<0.001). Dietary oleate partially prevented MCD diet-induced serum level increases in aspartate aminotransferase and alanine aminotransferase (P<0.001, respectively). The mRNA expressions of hepatic monocyte chemoattractant protein 1, tumor necrosis factor-α and matrix metalloproteinase-9 were increased in MCD diet-fed mice, and this overexpression of inflammatory molecules was prevented by dietary oleate (P<0.001). Hepatic pericellular fibrosis was observed in MCD diet-fed mice, and dietary oleate prevented this fibrosis. Altogether, dietary oleate prevented MCD diet-induced hepatic steatosis, inflammation and fibrosis. ConclusionDietary oleate has beneficial effects in every step of NAFLD development and progression and could be a nutritional option for NAFLD prevention and treatment.
-
Citations
Citations to this article as recorded by - Bidirectional association between NAFLD and gallstone disease: a systematic review and meta-analysis of observational studies
Shengying Gu, Shanshan Hu, Shuowen Wang, Chendong Qi, Chenyang Shi, Guorong Fan
Expert Review of Gastroenterology & Hepatology.2023; 17(3): 283. CrossRef - The Effect of Bioactive Aliment Compounds and Micronutrients on Non-Alcoholic Fatty Liver Disease
Camelia Munteanu, Betty Schwartz
Antioxidants.2023; 12(4): 903. CrossRef - Single‐cell transcriptomics stratifies organoid models of metabolic dysfunction‐associated steatotic liver disease
Anja Hess, Stefan D Gentile, Amel Ben Saad, Raza‐Ur Rahman, Tim Habboub, Daniel S Pratt, Alan C Mullen
The EMBO Journal.2023;[Epub] CrossRef - Histopathological Examination of the Effects of Tocilizumab and Dexamethasone on the Liver in Rats of Oleic Acid induced Acute Lung Injury
Funda TERZİ, Hüseyin Serkan EROL
Balıkesır Health Sciences Journal.2022;[Epub] CrossRef - Identifying Lipid Metabolites Influenced by Oleic Acid Administration Using High-Performance Liquid Chromatography–Mass Spectrometry-Based Lipidomics
Chao Xu, Dan Song, Askild L. Holck, Youyou Zhou, Rong Liu
ACS Omega.2020; 5(20): 11314. CrossRef - Causative and Sanative dynamicity of ChREBP in Hepato-Metabolic disorders
P. Vineeth Daniel, Prosenjit Mondal
European Journal of Cell Biology.2020; 99(8): 151128. CrossRef - PPARδ attenuates hepatic steatosis through autophagy-mediated fatty acid oxidation
Lei Tong, Long Wang, Shuangshuang Yao, Lina Jin, Jian Yang, Yifei Zhang, Guang Ning, Zhiguo Zhang
Cell Death & Disease.2019;[Epub] CrossRef - Butyrate Protects Mice Against Methionine–Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels
Jianzhong Ye, Longxian Lv, Wenrui Wu, Yating Li, Ding Shi, Daiqiong Fang, Feifei Guo, Huiyong Jiang, Ren Yan, Wanchun Ye, Lanjuan Li
Frontiers in Microbiology.2018;[Epub] CrossRef - Olive oil combined with Lycium barbarum polysaccharides attenuates liver apoptosis and inflammation induced by carbon tetrachloride in rats
Yun-Yun Chiang, Jane C.-J. Chao
Journal of Functional Foods.2018; 48: 329. CrossRef - Dietary oleic acid regulates hepatic lipogenesis through a liver X receptor-dependent signaling
Simon Ducheix, Alexandra Montagner, Arnaud Polizzi, Frédéric Lasserre, Marion Régnier, Alice Marmugi, Fadila Benhamed, Justine Bertrand-Michel, Laila Mselli-Lakhal, Nicolas Loiseau, Pascal G. Martin, Jean-Marc Lobaccaro, Laurent Ferrier, Catherine Postic,
PLOS ONE.2017; 12(7): e0181393. CrossRef - Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β
Simon Ducheix, Maria Carmela Vegliante, Gaetano Villani, Nicola Napoli, Carlo Sabbà, Antonio Moschetta
Cellular and Molecular Life Sciences.2016; 73(20): 3809. CrossRef - Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway
Young Mi Song, Yong-ho Lee, Ji-Won Kim, Dong-Sik Ham, Eun-Seok Kang, Bong Soo Cha, Hyun Chul Lee, Byung-Wan Lee
Autophagy.2015; 11(1): 46. CrossRef - Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease
Sanja Stojsavljević
World Journal of Gastroenterology.2014; 20(48): 18070. CrossRef - Microglial Cell Activation Increases Saturated and Decreases Monounsaturated Fatty Acid Content, but Both Lipid Species are Proinflammatory
Emily B. Button, Andrew S. Mitchell, Marcia M. Domingos, Jessica H.‐J. Chung, Ryan M. Bradley, Ashkan Hashemi, Phillip M. Marvyn, Ashley C. Patterson, Ken D. Stark, Joe Quadrilatero, Robin E. Duncan
Lipids.2014; 49(4): 305. CrossRef - Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse
Jesse D. Riordan, Joseph H. Nadeau
Mammalian Genome.2014; 25(9-10): 473. CrossRef - Rapid chromatographic method to decipher distinct alterations in lipid classes in NAFLD/NASH
Stephan Laggai, Yvette Simon, Theo Ranssweiler, Alexandra K Kiemer, Sonja M Kessler
World Journal of Hepatology.2013; 5(10): 558. CrossRef - Dimethyl sulfoxide reduces hepatocellular lipid accumulation through autophagy induction
Young Mi Song, Sun-Ok Song, Yong-Keun Jung, Eun-Seok Kang, Bong Soo Cha, Hyun Chul Lee, Byung-Wan Lee
Autophagy.2012; 8(7): 1085. CrossRef
- Postprandial Triglyceride Is Associated with Fasting Triglyceride and HOMA-IR in Korean Subjects with Type 2 Diabetes
-
Seo Hee Lee, Byung-Wan Lee, Hee Kwan Won, Jae Hoon Moon, Kwang Joon Kim, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
-
Diabetes Metab J. 2011;35(4):404-410. Published online August 31, 2011
-
DOI: https://doi.org/10.4093/dmj.2011.35.4.404
-
-
4,846
View
-
43
Download
-
14
Crossref
-
Abstract
PDFSupplementary MaterialPubReader
- Background
Recent studies indicate postprandial triglyceride (TG) had a better association with cardiovascular events and metabolic syndrome than fasting TG. The authors of the present study investigated the metabolic and clinical relevance of postprandial TG. MethodsIn a cross-sectional retrospective study, the authors of the present study compared fasting and postprandial TG and analyzed the relationship between postprandial TG and various demographic and metabolic parameters in 639 Korean subjects with type 2 diabetes (T2D, group I, n=539) and impaired fasting glucose (IFG, group II, n=100) after ingestion of a standardized liquid meal (total 500 kcal, 17.5 g fat, 68.5 g carbohydrate, and 17.5 g protein). ResultsFasting and postprandial TG were significantly correlated (r=0.973, r=0.937, P<0.001) in group I and II, respectively. Of the variables, total cholesterol, waist circumference and body mass index were significantly correlated with fasting and postprandial TG in both groups. Only postprandial TG showed a significant correlation with glucose metabolic parameters (e.g., postprandial glucose, homeostatic model assessment of insulin resistance [HOMA-IR], and fasting C-peptide) in subjects with T2D. Multiple regression analysis showed fasting TG and HOMA-IR could be predictable variables for postprandial TG in subjects with T2D. ConclusionPostprandial TG was very strongly correlated with fasting TG. The authors of the present study suggest insulin resistance may be more associated with postprandial TG than fasting TG in Korean T2D patients on a low-fat diet.
-
Citations
Citations to this article as recorded by - Impaired ketogenesis is associated with metabolic-associated fatty liver disease in subjects with type 2 diabetes
Sejeong Lee, Jaehyun Bae, Doo Ri Jo, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Frontiers in Endocrinology.2023;[Epub] CrossRef - Postprandial lipaemia following consumption of a meal enriched with medium chain saturated and/or long chain omega-3 polyunsaturated fatty acids. A randomised cross-over study
Grace Austin, Jessica JA. Ferguson, Rohith N. Thota, Harjinder Singh, Tracy Burrows, Manohar L. Garg
Clinical Nutrition.2021; 40(2): 420. CrossRef - Effects of fatty acids composition in a breakfast meal on the postprandial lipid responses: a systematic review and meta-analysis of randomised controlled trials
Yuanhang Yao, Sheri Xueqi Pek, Darel Wee Kiat Toh, Xuejuan Xia, Jung Eun Kim
International Journal of Food Sciences and Nutrition.2020; 71(7): 793. CrossRef - The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk
Pratik B Sandesara, Salim S Virani, Sergio Fazio, Michael D Shapiro
Endocrine Reviews.2019; 40(2): 537. CrossRef - Determinant of postprandial triglyceride levels in healthy young adults
Tri J.E. Tarigan, Anandhara I. Khumaedi, Syahidatul Wafa, Michael Johan, Murdani Abdullah, Ingrid S. Surono, Dicky L. Tahapary
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(3): 1917. CrossRef - Impact of the triglyceride level on coronary plaque components in female patients with coronary artery disease treated with statins
Motoki Yamashita, Atsushi Iwata, Yuta Kato, Makito Futami, Satoshi Imaizumi, Takashi Kuwano, Amane Ike, Makoto Sugihara, Hiroaki Nishikawa, Bo Zhang, Shin’ichiro Yasunaga, Keijiro Saku, Shin-ichiro Miura
Heart and Vessels.2018; 33(10): 1175. CrossRef - Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals
Haseeb A. Khan, Samia H. Sobki, Aishah Ekhzaimy, Isra Khan, Mona A. Almusawi
Saudi Journal of Biological Sciences.2018; 25(8): 1729. CrossRef - Postprandial C‐peptide to glucose ratio as a predictor of β‐cell function and its usefulness for staged management of type 2 diabetes
Eun Young Lee, Sena Hwang, Seo Hee Lee, Yong‐ho Lee, A Ra Choi, Youngki Lee, Byung‐Wan Lee, Eun Seok Kang, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee
Journal of Diabetes Investigation.2014; 5(5): 517. CrossRef - Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease
Robert S. Rosenson, Michael H. Davidson, Benjamin J. Hirsh, Sekar Kathiresan, Daniel Gaudet
Journal of the American College of Cardiology.2014; 64(23): 2525. CrossRef - The effect of insulin resistance on postprandial triglycerides in Korean type 2 diabetic patients
Kyeong Hye Park, Kwang Joon Kim, Byung-Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
Acta Diabetologica.2014; 51(1): 15. CrossRef - Acute effects of an oral supplement of (−)-epicatechin on postprandial fat and carbohydrate metabolism in normal and overweight subjects
Gabriela Gutiérrez-Salmeán, Pilar Ortiz-Vilchis, Claudia M. Vacaseydel, Ivan Rubio-Gayosso, Eduardo Meaney, Francisco Villarreal, Israel Ramírez-Sánchez, Guillermo Ceballos
Food & Function.2014; 5(3): 521. CrossRef - A comparative study of broccoli sprouts powder and standard triple therapy on cardiovascular risk factors following H.pylori eradication: a randomized clinical trial in patients with type 2 diabetes
Parvin Mirmiran, Zahra Bahadoran, Mahdieh Golzarand, Homayoun Zojaji, Fereidoun Azizi
Journal of Diabetes & Metabolic Disorders.2014;[Epub] CrossRef - Association of higher resistin levels with inflammatory activation and endothelial dysfunction in patients with essential hypertension
Chang FANG, Juan LEI, Shu-xian ZHOU, Yu-ling ZHANG, Gui-yi YUAN, Jing-feng WANG
Chinese Medical Journal.2013; 126(4): 646. CrossRef - Epicardial adipose tissue thickness is an indicator for coronary artery stenosis in asymptomatic type 2 diabetic patients: its assessment by cardiac magnetic resonance
Hyun Kim, Kwang Kim, Hye-Jeong Lee, Hee Yu, Jae Moon, Eun Kang, Bong Cha, Hyun Lee, Byung-Wan Lee, Young Kim
Cardiovascular Diabetology.2012; 11(1): 83. CrossRef
|
KDA
